|
|
|
|
Cell Cycle Kinases as Therapeutic Targets for Cancer
The article, which is featured in the July 2009 online issue of Nature Reviews/Drug Discovery, was written by Antonio Giordano, M.D., Ph.D., the Director of the Sbarro Institute for Cancer Research and Molecular Medicine, the Director of...
|
|
|
Cell Cycle Kinases as Therapeutic Targets for Cancer
Newswise - A comprehensive overview that explores the prospects and progress of synthetic inhibitors to target cell cycle kinases in cancer forecasts that 'novel compounds with increased potency, improved kinase specificity and...
|
|
|
Immune-based therapy for chronic hepatitis C
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Journal of Leukocyte Biology, 07/02/09 Print Save in My Library Free Abstract Chang DY et al.- These immune-based therapies for chronic HCV...
|
|
|
Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdomi
_ Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdomi.
|
|
|
Osteoporosis undertreated in COPD patients
MedWire News: Around one in five patients with chronic obstructive pulmonary disease (COPD) who are assigned to pulmonary rehabilitation have osteoporosis, but most are not receiving guidelines recommended medication to prevent bone...
|
|
|
Important Modulator Of Immune Cell Entry Into The Brain Discovered
Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells.A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The...
|
|
|
SCANCELL HOLDINGS PLC - Merck Serono Licensing Agreement
(PR Newswire Europe via COMTEX) -- MRK | Quote | Chart | News | PowerRating -- e>02/07/2009 GB00B39J5N63 Scancell Holdings Plc ('Scancell Holdings' or the 'Company') Scancell licenses key ImmunoBody(R) patents from Merck Serono...
|
|
|
REG-Scancell Holdings Plc: Merck Serono Licensing Agreement
GB00B39J5N63 Scancell Holdings Plc ('Scancell Holdings' or the 'Company') Scancell licenses key ImmunoBody patents from Merck Serono Scancell Holdings Plc, the parent company of Scancell Limited ('Scancell'), the developer of therapeutic...
|
|
|
25 years after HIV discovered, vaccine search goes on
The despair that set in after the failure of the latest effort to develop an AIDS vaccine has given way to a renewed determination on the part of the scientific community, says the Canadian scientist leading an international effort to...
|
|
|
25 years after HIV discovered, vaccine search goes on
The despair that set in after the failure of the latest effort to develop an AIDS vaccine has given way to a renewed determination on the part of the scientific community, says the Canadian scientist leading an international effort to...
|
|
|
2. Personalized Anti-Cancer Vaccine, BiovaxID[R], Targeting B-cell Lymphomas
Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine Phase III Study Results to Be Presented at 'Best of ASCO' in Paris TAMPA, Fla.-- Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of...
AllBusiness Champions of Small Business:
Jul 1 2009 4:59PM
Matching: leukemia cell chronic
|
Find similar documents
|
|
|
|
Lifespan Of HIV-infected Cells Might Be Shorter Than Previously Believed
Dutch-sponsored researcher Christian Althaus has used mathematical models to demonstrate that cells infected with HIV could die even sooner than was thought until now.If infected cells have a shorter lifespan then this...
|
|
|
Peptic Ulcer Bacterium Alters The Body's Defence System
Helicobacter pylori survives in the body by manipulating important immune system cells.This is shown in a thesis from the Sahlgrenska Academy. The discovery may lead to new treatments against the common peptic ulcer bacterium.
|
|
|
Nuclear-plant workers face elevated cancer risk: report
The 30-page Exposure to Radiation and Health Outcomes, commissioned by the Saskatchewan Union of Nurses and the Canadian Centre for Policy Alternatives, found that chronic exposure to low doses of radiation causes the higher risk.A...
|
|
|
Childhood cancer survivors sicker as adults
People who survived childhood brain cancer were 13 times more likely to die within 30 years than others their age, a study found.The most common cause of death was recurrence of their brain cancer, according to research in the July 1...
|
|
|
UCB (BE) - UCB and Biogen Idec Discontinue Phase II Clinical Trial of CDP323
at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS).Preliminary interim efficacy...
|
|
|
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patie
Biovest International, Inc.(Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID, Biovest's personalized therapeutic anti-cancer vaccine, is available on a...
|
|
|
Minicells defeat drug resistant cancer
Researchers led by Sydney-based biotechnology company, EnGeneIC, have reported in Nature Biotechnology that bacterially-derived minicells can be used to target previously resistant cancerous tumours, presenting the possibility of treating...
|
|
|
Biovest' BiovaxID Now Available In Europe
BiovaxID, to stimulate the patient' own immune system to recognize and destroy cancerous B-cells Biovest, a subsidiary of Accentia Biopharmaceuticals, has announced that BiovaxID, a personalized therapeutic anti-cancer vaccine, is...
|
|
|
Lifespan of HIV-infected cells might be shorter than previously anticipated
Dutch-sponsored researcher Christian Althaus has used mathematical models to demonstrate that cells infected with HIV could live even shorter than was thought until now.If infected cells have a shorter lifespan then this...
|
|
|
Peptic ulcer bacterium alters the body's defence system
Helicobacter pylori survives in the body by manipulating important immune system cells.This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden. The discovery may lead to new treatments against the...
|
|
|
Innate Pharma Reports Positive Phase IIa Clinical Results For Iph 1101 In Type C Viral Hepatitis
Innate Pharma (Euronext Paris: FR0010331421 IPH) reports positive results for its first Phase IIa clinical trial with IPH 1101 (a small-molecule ?d T cell agonist) in patients with type C viral hepatitis (HCV).In this open...
|
|
|
UCB and Biogen Idec discontinue Phase II clinical trial of CDP323
at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS).Preliminary interim efficacy...
|
|
|
UCB and Biogen Idec discontinue Phase II clinical trial of CDP323
Preliminary interim efficacy analysis showed no clinically relevant benefit for patients Brussels (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of...
|
|
|
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
AbstractThe mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy; however, CLL is still an incurable disease with resistance to therapy developing in the majority of patients.In recent years, our...
Nature Clinical Practice Oncology:
Jun 29 2009 7:42AM
Matching: leukemia t cell chronic
|
Find similar documents
|
|
